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Immune thrombocytopenia is an autoimmune disease with abnormal T cell immunity. Cytotoxic T cells, abnormal T
regulatory cells, helper T cell imbalance, megakaryocyte maturation abnormalities and abnormal T cell anergy are
involved in the pathogenesis of this condition. The loss of T cell-mediated immune tolerance to platelet auto-antigens
plays a crucial role in immune thrombocytopenia. The induction of T cell tolerance is an important mechanism
by which the pathogenesis and treatment of immune thrombocytopenia can be studied. Studies regarding the
roles of the new inducible costimulator signal transduction pathway, the ubiquitin proteasome pathway, and the
nuclear factor kappa B signal transduction pathway in the induction of T cell tolerance can help improve our
understanding of immune theory and may provide a new theoretical basis for studying the pathogenesis and
treatment of immune thrombocytopenia.
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Immune thrombocytopenia (ITP), also known as idiopathic
thrombocytopenic purpura, is an immune-mediated disease
of adults and children that is characterized by excessive
platelet destruction and decreased platelet production. At
the Italian Vicenza Consensus Conference in October
2007, the experts of the ITP International Working Group
decided to use the term “immune” in place of “idiopathic”
to emphasize the immune-mediated mechanism of the
disease.
ITP pathogenesis is very complicated. Studies of ITP
pathogenesis show that the direct dissolution of antigen-
specific antibodies mediates platelet destruction and that
cytotoxic T cells (CTL) increase platelet destruction. In
addition to platelet destruction, an immune-mediated
megakaryocyte maturation abnormality and abnormal
apoptosis result in decreased platelet production in ITP
patients. T cell immune abnormalities play crucial roles in
ITP pathogenesis. These T cell abnormalities are character-
ized by the excessive activation and proliferation of platelet
auto-antigen-reactive CTLs [1,2], abnormal numbers and
functions of T regulatory cells (Tregs) [3,4], production* Correspondence: houming@medmail.com.cn
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unless otherwise stated.of abnormal helper T (Th) cells [5,6], megakaryocyte
maturation abnormalities [7,8], abnormal T cell anergy
[9,10], and other features [Figure 1].
ITP and thrombotic thrombocytopenic purpura (TTP)
are distinct diseases that are differentially diagnosed
by measuring the serum ADAMTS13 concentration.
ADAMTS13 is a von Willebrand factor-cleaving protease
that belongs to the ADAMTS gene family. The detection
of ADAMTS-13 can provide useful information in dis-
tinguishing between ITP and TTP [11,12]. Intravenous
immunoglobulin (IVIG) administration is a common
treatment for ITP and TTP [13].
New studies of the roles of the ICOS/ICOS-L co-stimula-
tory signal transduction pathways, ubiquitin proteasome
pathway and NF-κB signal transduction pathway in the
induction of T cell tolerance may provide a new theoretical
basis for studying the pathogenesis and treatment of ITP.Mechanism of action of cytotoxic T cells in ITP
CTLs play an important role in human cellular and
tumor immunity. CTLs can kill tumor cells or the cells
infected with bacteria or viruses by programming the cells
to undergo apootosis. Memory engraftment with tumor-
specific CTLs provides long-term protection against tumors
[14]. Tumor cell-derived exosome-targeted dendritic cells
can stimulate stronger CD8+ CTL responses and anti-his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 T cell immune abnormalities in ITP pathogenesis. Immune thrombocytopenia pathogenesis is a complicated process. T cell immune
abnormalities are involved in ITP pathogenesis. These abnormalities include platelet auto-antigen reactive cytotoxic T cells, abnormal numbers
and functions of T regulatory cells, loss of Th1/Th2 balance, megakaryocyte maturation abnormalities and abnormal T cell anergy.
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the cytotoxic activity of CTLs through the phenotypic
modulation of tumor cells [16].
Leukotriene B4 can augment the activity of human
cytotoxic cells [17]. CTL activation requires help from
CD4+ T cells, which provide this help indirectly via the
modification of antigen-presenting cells [18]. CD4+ T cells
play an important role in the initiation and persistence of
CD8+ T cell responses. Active CD4+ helper T cells directly
stimulate CD8+ cytotoxic T lymphocyte responses [19].
CTLs can also induce the lysis of autologous platelets.
Platelet lysis mediated by CD8+ T cells has been demon-
strated to be involved in ITP pathogenesis [20,21]. In ITP
patients in whom anti-platelet auto-antibodies cannot be
detected, CTL-mediated platelet lysis is higher than in the
healthy control group. In the remitted ITP patients, the
level of platelet lysis induced by CTLs was not signifi-
cantly different from that in the normal control group.
Mechanisms of regulatory T cells in ITP
Tregs are decreased in number or can exhibit defective
suppressive functions in patients with ITP. CD4 +CD25+Tregs play critical roles in the maintenance of peripheral
immune tolerance. Platelet glycoprotein (GP)-specific
induced Tregs could be generated de novo from non-
regulatory CD4 +CD25–CD45RA + cells in ITP patients,
and these cells can induce antigen-specific immune
suppression.
Tregs play crucial roles in the induction and mainten-
ance of immune tolerance. Indirubin, a traditional Chinese
medicine, has been used in the treatment of chronic
myelocytic leukemia and some autoimmune diseases.
The ratios of CD4 + CD25+ Treg cells or CD4 + CD25 +
Foxp3+ Treg cells to CD4+ T cells in the peripheral blood,
lymph nodes, and spleens of indirubin-treated mice were
enhanced significantly compared with non-treated con-
trols. Furthermore, splenic CD4 + CD25+ Treg cells from
the indirubin-treated mice were able to suppress the
immune response to alloantigens.
These experimental data suggest that the injection of
indirubin into ITP mice significantly increases the number
of peripheral blood Tregs. The number of thymus Tregs is
higher in ITP mice than in healthy control mice. In
addition, indirubin injection significantly increases the
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that indirubin promotes immune tolerance in ITP [22].
The cytokine transforming growth factor-beta (TGF-β)
is a central player in maintaining the immune response
balance. The dominant function of TGF-β is to regulate
peripheral immune homeostasis [23]. In vitro experiments
using TGF-β and glycoprotein (GP) IIb/IIIa-loaded den-
dritic cells showed that CD4 + CD25-CD45RA + T cells
could be induced to become GPIIb/IIIa-specific CD4 +
CD25 + FOXP3+ regulatory T cells with immune suppres-
sive functions. In addition, tolerogenic dendritic cells are
involved in the regulation of immune functions [3].
Toll-like receptors (TLRs) play an important role in
defending the host against pathogenic microbes through
the induction of inflammatory cytokines and type I
interferons. Furthermore, TLRs play roles in shaping
pathogen-specific humoral and cellular adaptive immune
responses [24].
TLRs are the major molecules involved in the immune
regulatory process. TLR and TGF-signaling pathways are
also involved in platelet glycoprotein-specific immune
tolerance. These findings increase our understanding
of the mechanisms of induction and maintenance of
auto-antigen-specific immune tolerance. Antigen-specific
induced Tregs for targeted immunotherapy may be a
useful therapy for autoimmune diseases such as ITP [3].
The role of the Th1/Th2 balance in ITP
The Th1/Th2 balance is important to normal human
immunity. Th1 cells primarily secrete the inflammatory
cytokines IL-2, IL-12, interferon-gamma (IFN-γ) and
tumor necrosis factor-beta (TNF-β). These cytokines
mediate immune responses associated with cytotoxicity
and local inflammation and are involved in cellular im-
munity and the formation of delayed-type hypersensitivity
inflammation. Th1 cells are also known as inflammatory
T cells. Th2 cells primarily secrete the inflammatory cyto-
kines IL-4, IL-5, IL-6 and IL-10. The main function of
these cytokines is to stimulate B cell proliferation and
antibody production. Th2 cells are predominantly
associated with humoral immunity. Some diterpene
medicines modulate the function of human dendritic
cells in a manner that favors Th2 cell polarization; this
modulation could have therapeutic implications for
autoimmune diseases [25]. Signal transducers and activa-
tors of transcription (STAT)-6 inhibits T-bet-independent
Th1 cell differentiation by suppressing IL-12-STAT-4
signaling [26]. The Notch ligand mRNA levels of human
APCs are predictive of Th1/Th2-promoting activities [27].
The cause of Th1 lymphocyte bias abnormalities in ITP
remains poorly understood; however, uncontrolled Th-1
lymphocyte activation may be an important mechanism
of ITP. Treatment with a large dose of dexamethasone
can increase the levels of IL-4, IL-10, and TGF-β. Inrelapsed ITP patients, the Th1-type cytokine spectrum
returns to the dominant position after treatment with
dexamethasone [28]. IL-18, a member of the IL-1 cytokine
family, is widely expressed in monocytes/macrophages,
CD4+ T cells, NK cells, and other cell types. Furthermore,
IL-18 promotes Th1 responses by stimulating the produc-
tion of IFN-γ by T lymphocytes and natural killer (NK)
cells via IL-18R, which dominate in ITP. A previous study
confirmed that the plasma and mRNA levels of both
IFN-γ and IL-18 in active ITP patients were increased
significantly compared with the levels in healthy controls.
The balance of IL-18/IL-18BP is involved in the progression
of ITP. In addition, patients with active ITP have signifi-
cantly increased IL-18 levels in vivo but decreased IL-18BP
levels. This result suggests that the IL-18/IL-18BP ratio is
positively correlated with the Th1/Th2 ratio in ITP patients
[29]. In addition, high-dose dexamethasone treatment
can restore the Th1/Th2 balance by regulating the IL-18/
IL-18BP ratio [30]. The expression of Notch signaling
molecules and the level of IL-17 was not significantly
different between the healthy controls and the ITP patients
[31]. However, the number of CD3 +CD8-IL-17+ T cells
was higher in ITP patients than in healthy controls. IL-21+
T cells and Th17 cells were also found to be positively
correlated in ITP patients [32,33]. The expression of IL-17
was decreased in ITP patients [34,35]. In summary, ITP
patients demonstrate a Th1-type cytokine bias [36].
Immune-mediated megakaryocyte maturation abnormality
In vitro studies have provided evidence for the autoanti-
body-induced suppression of megakaryocytopoiesis. Mega-
karyocyte production and maturation are reduced in the
plasma of ITP patients. ITP plasma boosts megakaryocyte
quantity but impairs the quality, thereby significantly
decreasing polyploidy cells and platelet release.
CD8+ T cells can significantly inhibit the apoptosis of
bone marrow megakaryocytes, thereby inhibiting platelet
production in vitro. The co-culture of autologous CD8+ T
cells and bone marrow megakaryocytes with dexa-
methasone can significantly improve the inhibitory effect
of CD8+ T cells on the proliferation of bone marrow
megakaryocytes [7].
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) belongs to the TNF super-family of proteins.
Some studies have suggested that that TRAIL is involved
in the pathogenesis of certain autoimmune diseases
[37]. Decreased TRAIL levels might contribute to impaired
megakaryocyte apoptosis. Human megakaryocytes cultured
in vitro express TRAIL on their surfaces. Similarly,
activated platelets expressed both membrane-bound and
soluble TRAIL [38]. TRAIL can promote the maturation
and apoptosis of megakaryocytes.
TRAIL expression on megakaryocytes and the TRAIL
concentrations in the plasma and cell culture supernatants
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in healthy controls. Megakaryocyte apoptosis mediated
by TRAIL in the plasma of ITP patients may be a poten-
tial mechanism by which the megakaryocyte number
increases in vitro. These experimental results suggest
that megakaryocytes in ITP exhibit a low percentage of
apoptosis, a low expression of TRAIL, and a high expres-
sion of Bcl-xL. The decreased apoptosis of megakaryocytes
also contributes to in vitro dysmegakaryocytopoiesis and
reduced platelet production. The abnormal expression of
TRAIL in plasma and TRAIL and Bcl-xL in megakaryo-
cytes may serve important functions in the pathogenesis
of impaired megakaryocyte apoptosis in ITP [8].
Mechanisms of T cell anergy in ITP
The induction of autoreactive T cell anergy may reverse
T cell-mediated abnormal immunity in ITP. Cytotoxic
T lymphocyte associated antigen 4-immunoglobulin
(CTLA4-Ig) and/or cyclosporine A (CsA) can induce
platelet antigen-specific T cell anergy in vitro. T cell
anergy can be induced by the excessive consumption
of IL-2. The addition of high doses of exogenous IL-2
can reverse the anergic state of T cells. CTLA4-Ig can
be used to further explore the mechanisms by which
self-reactive T cells from patients with chronic ITP induce
the platelet-specific anergy of T cells. Results have shown
that CTLA4-Ig can induce the transformation of ITP
autoreactive T cells into anergic T cells that lack immuno-
modulatory effects. CTLA4-Ig can further inhibit the T
cell proliferation reaction of platelets. In most ITP
patients, CTLA4-Ig and/or CsA induce tolerance to
platelet antigens through anergy T cells. This tolerance
can be overcome by stimulation with unrelated antigens,
demonstrating its platelet specificity. Anergy is associated
with a lack of IL-2 and can be overcome by exogenous
IL-2. Hence, IL-2 suppression is crucial for the induction
of platelet-specific anergy.
Therefore, inducing the anergy of autoreactive T cells
may become a new therapeutic goal for the treatment of
ITP. CTLA4-Ig may be used in the treatment of ITP,
and combination therapy with CTLA4-Ig and CsA should
be considered for treating refractory ITP [9,10].
Recent studies have shown that the loss of T cell
immune tolerance is involved in the pathogenesis of ITP
[39]. The recovery of T cell tolerance is an important goal
in ITP treatment.
Immune tolerance refers to the unresponsiveness of the
immune system after exposure and reexposure to certain
antigens, while still maintaining a normal immune response
to other antigens. Immune tolerance can be naturally
or artificially induced. Artificial induction has important
theoretical and practical significance. The current common
artificial methods for the induction of tolerance include
co-stimulatory signal blockage [9], oral antigen induction,antagonistic antigen induction, soluble antigen induction,
and immune deviation induction. Thorough research of
the ITP T cell immune tolerance pathways is crucial to
the identification of new mechanisms to recover ITP
tolerance. This research has important theoretical sig-
nificance for the diagnosis and treatment of ITP. T cell
immune tolerance may possibly be recovered through
the pathways described below.
New co-stimulatory signal pathway-inducible co-stimulator
(ICOS) pathway
Blocking ICOS co-stimulation pathways to inhibit the
activity of ITP T cells in immune tolerance induction
provides a theoretical basis for the mechanism and treat-
ment of ITP. Co-stimulatory signal blockage triggers T
cells to produce specific immune tolerance to antigens.
Previous studies have confirmed that the ITP CD28/B7
pathway is involved in T cell activation [40-42]. The B7
co-stimulation blockers CTLA4-Ig and CsA can block the
co-stimulatory signal pathway and induce T cell tolerance.
Blocking CD28 co-stimulation alone cannot induce T
cell immune tolerance, suggesting the presence of other
pathways that mediate T cell tolerance induction [2,43].
Additional research into the ICOS/ICOS-L co-stimulatory
signal pathway is necessary to identify new mechanisms
involved in ITP pathogenesis. Blocking the ICOS/ICOS-L
co-stimulatory signal transduction pathway could be a
new way to induce T cell tolerance in ITP.
ICOS is a newly discovered member of the CD28 family.
ICOS-ligand (ICOS–L) interactions can enhance the T
cell response to exogenous antigen, and the ICOS/
ICOSL co-stimulatory signal transduction pathway serves
an important function in cellular and humoral immunity
[44-46]. ICOS has an important and unique function in
immune responses. The CD28/B7 pathway serves import-
ant functions in the initial stage of T cell activation. In
this stage,T cells are induced to produce IL-2 and pro-
moted to proliferation. The ICOS pathway is principally
involved in the differentiation and effector stages of T
cell development; furthermore, this pathway regulates T
cell proliferation and differentiation [45,47,48].
The ICOS/ICOS-L co-stimulatory signal pathway is
important in the immune process. This pathway not
only regulates the immune response of Th1 and Th2 but
also promotes the proliferation and differentiation of B
cells and the formation of effector cells. It can also enhance
the killing effect of CTL and NK cells that is important in
the secondary immune response theory.
Inhibition of the ubiquitin proteasome pathway
Blocking the MHC class I antigen processing, presentation,
and nuclear factor kappa B (NF-κB) signal transduction sys-
tem can inhibit the proliferation of lymphocyte activation
and induce ITP T cell tolerance. These observations may
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ance induced by the proteasome system.
Proteasome inhibitors can inhibit proteasome activity
and interfere with the function of cells. Particularly, they
inhibit lymphocyte activation and proliferation. The
proteasome is involved in the major histocompatibility
complex (MHC)-I antigen presenting function by pro-
moting lymphocyte activation [49,50] and also plays a
role in NF-κB activation.
Given the functions of the proteasome in the immune
system, proteasome inhibitors can alter important immune
processes. First, the processing and presentation of the
MHC class I antigens are blocked by proteasome inhibitor
activation. As a result, the activation of lymphocytes is
inhibited, and immune tolerance is induced. Second, pro-
teasome inhibitors inhibit the proteasomal degradation of
the I kappa B (IκB) protein and trigger the inactivation of
NF-κB, thereby blocking the NF-κB signal transduction
system, inhibiting the activation and proliferation of
lymphocytes, and inducing immune tolerance.
The transcription factor NF-κB belongs to the Rel
family. It is principally involved in immune and inflam-
matory responses, transcription, and cell proliferation
and differentiation. NF-κB activation is regulated by its
inhibitory factor (IκB, inhibitor of NF-κB). In the resting
state, two NF-κB proteins bind a single unit of IκB to
form a trimer in the cytoplasm. Extracellular stimulation
causes IκB to be degraded by the proteasome ubiquitin.
Then, NF-κB is dissociated from the trimer and translo-
cates to the nucleus as a transcription factor where it
regulates gene expression, cell proliferation, and differ-
entiation [51-53].
The proteasome inhibitor bortezomib can stabilize IκB
by inhibiting the proteasome 20S subunit activity, NF-κB
activity, and lymphocyte proliferation and differentiation
[54-58]. Therefore, the administration of bortezomib
may become a new way to induce immune tolerance.
This finding provides a theoretical basis for inducing
ITP T cell tolerance by blocking the proteasome pathway
and the NF-κB signaling pathway.Conclusions and future directions
ITP is an autoimmune disease with abnormal T cellular
immunity. The loss of T cell tolerance plays an import-
ant role in the pathogenesis of ITP. The induction of T
cell tolerance may be a promising new therapeutic strategy
for the treatment of ITP. However, additional prospective
studies of the roles of the ICOS/ICOS-L co-stimulatory sig-
nal transduction pathway, ubiquitin proteasome pathway,
and NF-κB signal transduction pathway in the induction of
T cell immune tolerance are required. Understanding these
pathways may provide a new theoretical basis for the
pathogenesis and treatment of ITP.Competing interests
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